Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2020
|
| gptkbp:atccode |
L01 BC02
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:healthcare |
April 2020
|
| https://www.w3.org/2000/01/rdf-schema#label |
Jelmyto
|
| gptkbp:ingredients |
mitomycin
|
| gptkbp:manufacturer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:marketed_in_country |
gptkb:United_States
|
| gptkbp:packaging |
single-use vials
|
| gptkbp:route_of_administration |
intravesical administration
|
| gptkbp:side_effect |
fatigue
nausea urinary tract infection hematuria bladder irritation |
| gptkbp:storage |
refrigerated
|
| gptkbp:structure |
C15 H18 N4 O5
|
| gptkbp:used_for |
treatment of upper tract urothelial cancer
|
| gptkbp:bfsParent |
gptkb:Uro_Gen
|
| gptkbp:bfsLayer |
6
|